9 results within Condition Category: Haematological Disorders Remove filter Countries of recruitment: France Remove filter

• ISRCTN50040185 : NuProtect: Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe haemophilia A

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  22/10/2013

• ISRCTN37539930 : Clinical study to evaluate the efficacy and safety of immunoglobulin intravenous (human) 10% (NewGam) in Primary Immune Thrombocytopenia

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  27/02/2013

• ISRCTN99606748 : Clinical study in which the long term effect of Human-cl rhFVIII is investigated in children with severe haemophilia A, who were previously treated in the GENA-03 study

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  03/01/2012

• ISRCTN02245668 : The tolerability of Octagam® 5% and Octagam® 10%

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  25/10/2011

• ISRCTN30718752 : Gene therapy for Wiskott-Aldrich Syndrome (WAS)

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  20/05/2011

• ISRCTN71212110 : Prospective clinical study in children with severe haemophilia A to investigate clinical efficacy, immunogenicity, pharmacokinetics, and safety of Human-cl rhFVIII

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  23/02/2011

• ISRCTN41980964 : A Randomized Controlled Study in Newly Diagnosed Severe Aplastic Anemia Patients Receiving Antithymocyte Globulin (ATG), Cyclosporin A, with or without Granulocyte Colony Stimulating Factor (G-CSF)

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  21/10/2005

• ISRCTN05896089 : A randomised, multicentre, open label, phase Il study to evaluate the safety, tolerability, pharmacokinetics and the effects on liver iron concentration of repeated doses of 10 mg/kg/day of ICL670 relative to deferoxamine in sickle cell disease (SCD) patients with transfusional haemosiderosis

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  05/09/2003

• ISRCTN93355192 : A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in β-thalassaemia patients with transfusional haemosiderosis

  Overall trial status

  Completed

  Recruitment status

  No longer recruiting

  Published

  France

  Haematological Disorders

  Date assigned

  05/09/2003